The Knoxville Community Development Corporation broke ground on Phase 2 of the Transforming Western initiative Wednesday.

A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

At U.S. 27 and Rogers Road, $2.6 million in federal funding is being spent on a construction project that started in March in ...

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 Pioneering small-molecule program, NT-0796, targets chronic ...

The Knoxville Community Development Corporation broke ground on Phase 2 of the Transforming Western initiative, which will ...

Cellectar's Iopofosine I 131 earned FDA breakthrough therapy designation for relapsed Waldenstrom macroglobulinemia following ...

Synpulse, a global management consultancy with deep expertise in financial services, is pleased to announce the successful ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Rapt Therapeutics has conducted its second round of layoffs in just under a year, continuing a period of upheaval following ...

In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 ...

Sagimet Biosciences Inc. (NASDAQ:SGMT) said on Wednesday that denifanstat met all primary and secondary endpoints in a Phase ...

BeOne Medicines' robust financial outlook is driven by zanubrutinib's rapid sales growth and anticipated positive cash flow.